Why Order Urine Protein-Creatinine Ratio and Complement C5b-9
You order a urine protein-creatinine ratio (UPCR) to quantify proteinuria in suspected or diagnosed glomerular disease, and complement C5b-9 (membrane attack complex) to assess active complement-mediated glomerular injury, particularly when membranous nephropathy or other complement-driven glomerulopathies are suspected.
Urine Protein-Creatinine Ratio (UPCR)
Primary Indication
UPCR is the preferred method for quantifying proteinuria in glomerular disease management 1, 2. The KDIGO 2021 guidelines recommend:
- First morning UPCR is optimal for monitoring, particularly in pediatric patients where 24-hour collections are impractical 1
- Random spot UPCR has limitations due to temporal variation in protein and creatinine excretion 1
- 24-hour collections with UPCR measured on an aliquot represent a reasonable compromise when feasible 1
Clinical Performance
UPCR demonstrates strong correlation with 24-hour protein measurements (Pearson correlation 0.85) 3. The test characteristics are robust:
- UPCR ≥0.18 mg/dL maximizes sensitivity (91%) for detecting clinically significant proteinuria (≥300 mg/24h) 3
- UPCR <0.10 mg/dL effectively excludes significant proteinuria 3
- Area under ROC curve of 0.86 indicates high diagnostic performance 3
When to Use UPCR
Order UPCR when:
- Initiating or intensifying immunosuppression for glomerular disease 1
- Monitoring treatment response (proteinuria reduction is a key surrogate endpoint) 2
- Assessing disease activity in nephrotic syndrome
- Evaluating patients with suspected glomerulonephritis
Common pitfall: Random spot collections may miss orthostatic proteinuria; first morning specimens are preferred 1.
Complement C5b-9 (Membrane Attack Complex)
Primary Indication
Urinary C5b-9 (SC5b-9, MAC) measures terminal complement activation and reflects active complement-mediated glomerular injury 4, 5.
Specific Clinical Scenarios
Membranous Nephropathy (MN):
- C5b-9 is elevated in active MN, mirroring the pathophysiology seen in experimental Heymann nephritis 4
- Glomerular C5b-9 deposition occurs alongside C3b/C3c at early disease stages 5
- Urinary C5b-9/factor H ratio correlates negatively with creatinine clearance (r = 0.662, p < 0.01), indicating degree of ongoing complement activation and renal injury 5
C3 Glomerulopathy:
- Emerging evidence supports complement biomarker monitoring in C3G, particularly with new complement-targeted therapies 6
- Terminal complement blockade and factor B inhibition trials use proteinuria and complement markers as endpoints 6
Interpretation
- Normal urine: 80 ± 3 ng/mg urinary creatinine 4
- Elevated levels: 200-20,000 ng/mg UCr in glomerulopathies 4
- Stability: C5b-9 in fresh urine is stable for 3 hours at 37°C; freezing at -70°C artifactually raises levels 4
Clinical Utility
The C5b-9/factor H ratio provides insight into:
- Balance between complement activation and regulation 5
- Degree of ongoing glomerular complement injury 5
- Potential response to complement-targeted therapies 6
Algorithmic Approach
Order both tests when:
- Suspected membranous nephropathy → UPCR quantifies proteinuria severity; C5b-9 assesses immunologic activity
- C3 glomerulopathy evaluation → UPCR monitors disease activity; C5b-9 guides complement-targeted therapy decisions
- Nephrotic syndrome workup → UPCR establishes baseline proteinuria; C5b-9 helps differentiate complement-mediated etiologies
- Monitoring treatment response → Serial UPCR tracks proteinuria reduction; C5b-9 reflects immunologic remission
Critical caveat: C5b-9 measurement is not widely available in routine clinical laboratories and is primarily used in specialized nephrology centers or research settings. UPCR, by contrast, is standard clinical practice 1, 2.